Quadrant Future Tek Share Price Opens at ₹370 on Listing Day; Above Issue Price of ₹290

Quadrant Future Tek IPO opened for subscription on January 7, 2025, and closed on January 9, 2025.

It was a book-built issue of ₹290.00 crore. The issue was a fresh issue of 1.00 crore shares. The Quadrant Future Tek IPO price band was set at ₹275 to ₹290 per share.

On Day 3 of subscription, January 9, as of 6:19 PM, Quadrant Future Tek IPO was subscribed 195.96 times. QIBs subscribed 139.77x, NIIs subscribed 268.03x, and retail investors subscribed 256.46x.

The share allotment was finalised on January 10, 2025, and the shares were listed on BSE and NSE on January 14, 2025.

Quadrant Future Tek Share Price

On the listing day, on the NSE, Quadrant Future Tek share price opened at ₹370.00, up from its issue price of ₹290.00. At 10:24 AM, the share price was trading at ₹377.60, up by 2.05% from its opening price of ₹370.00. As of the same time, the stock touched its day’s high at ₹389.90. The company’s market cap was ₹1,516.40 crore.

On the BSE, at 10:25 AM, Quadrant Future Tek share price was trading at ₹378.85, up by 1.30% from its opening price of ₹374.00 and 30.84% up from its issue price of ₹290.00.

About Quadrant Future Tek Limited

Quadrant Future Tek is a research-driven company focused on developing next-generation Train Control and Signalling Systems under the KAVACH project of Indian Railways, aimed at ensuring the highest levels of safety and reliability for rail passengers. The company also operates a speciality cable manufacturing facility equipped with an Electron Beam Irradiation Centre. These speciality cables are utilised in railway rolling stock and the naval (defence) industry. Additionally, the facility is fully equipped with end-to-end infrastructure for the production of solar and EV cables.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Shoppers Stop Share Price Dips 1.46% Ahead of Q3 FY25 Results

Shoppers Stop Limited is gaining attention on Tuesday ahead of the Q3 FY 2025 financial results announcement.

On January 14, 2025, Shoppers Stop share price (NSE: SHOPERSTOP) opened at ₹612.00, down from its previous close of ₹605.30. At 10:01 AM, the share price of Shoppers Stop was trading at ₹596.45, down by 1.46% on the NSE. Notably, the stock touched its 52-week low at ₹575.00 recently on January 6, 2025.

Board Meeting Announcement

Earlier this month, in January 2025, the company announced that its Board of Directors would convene on Tuesday, January 14, 2025, to review the unaudited financial results for the quarter and the nine months ending December 31, 2024.

Financial Performance in Q2 FY 2025

In Q2 FY 2025, the company reported sales of ₹1,068 crore, a 4% increase compared to ₹1,025 crore in Q2 FY 2024. However, the company recorded a loss of ₹22 crore in Q2 FY 2025 compared to a profit of ₹2 crore in Q2 FY 2024.

About Shoppers Stop Limited

Shoppers Stop Ltd, established in 1991, is one of the leading retailers in India of premium fashion and beauty brands. As of December 31, 2022, it offers a portfolio of more than 800 brands and operates 271 stores across 50 cities nationwide.

 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Bharat Electronics Limited Secures Additional Orders Worth ₹561 Crore

Bharat Electronics Limited (BEL), a Navratna Defence Public Sector Undertaking, has announced securing additional orders worth ₹561 crores since its last disclosure on December 23, 2024.

These new orders include communication equipment, electro-optics, upgrades for SATCOM networks, radar and fire control systems, spares, and services.

With these orders, BEL’s total order intake for the current financial year has reached ₹10,362 crores, reinforcing its position as a key player in India’s defence manufacturing ecosystem.

Financial Performance Highlights: Q2 FY25 and H1 FY25

BEL demonstrated growth in Q2 FY25, with revenue from operations rising to ₹4,58,341 lakh compared to ₹3,99,332 lakh in Q2 FY24. Profit after tax for the quarter surged to ₹1,09,127 lakh, from ₹81,234 lakh in Q2 FY24.

For H1 FY25, revenue from operations stood at ₹8,78,218 lakh, reflecting a growth from ₹7,50,416 lakh in H1 FY24. Net profit for H1 FY25 was ₹1,86,741 lakh, marking an increase from ₹1,34,318 lakh in H1 FY24.

About Bharat Electronics Limited

Bharat Electronics Ltd was incorporated in 1954. The company is involved in the manufacturing and supplying of electronic equipment and systems to the defence sector. The company also has a limited presence in the civilian market.

On January 14, 2025, BEL share price opened at ₹263.00, touching the day’s high at ₹265.95, as of 9:46 AM on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Puravankara Reports 2% YoY Growth in Q3FY25 Sales

Puravankara Limited recorded notable financial and operational achievements for Q3 FY25 and the nine months ended December 31, 2024 (9MFY25).

The company reported sales of ₹1,265 crores for Q3 FY25, a 2% increase compared to ₹1,241 crores in Q3 FY24. For 9MFY25, sales value reached ₹3,724 crores, demonstrating strong momentum.

Customer Collections and Pricing Trends

Customer collections showed growth, increasing by 6% year-on-year (YoY) to ₹993 crores in Q3 FY25 compared to ₹941 crores in the same quarter of the previous year. For the nine-month period, customer collections surged 19%, reaching ₹2,991 crores compared to ₹2,515 crores in 9MFY24. Additionally, the average price realisation for Q3 FY25 increased significantly to ₹8,848 per square foot (sft), a 16% rise compared to ₹7,621 per sft in Q3 FY24.

Strategic Investments in Land Acquisition

Puravankara spent over ₹1,100 crores on land acquisitions during the fiscal year, securing a potential gross development value (GDV) of ₹10,500 crores. These investments align with the company’s long-term growth strategy and strengthen its position in the consolidating real estate market.

Market Outlook

The company stated that the real estate sector in India continues to witness strong foreign equity investments, which reached an all-time high of $11.4 billion in 2024. The absorption of over 70 million square feet of office space across six major cities during the year highlights robust commercial demand driven by Global Capability Centers (GCCs) and hiring growth.

While delays in approvals affected new launches in 9MFY25, Puravankara plans to expedite its pipeline with 15.70 million sq. ft of projects scheduled for launch between Q4 FY25 and Q1 FY26. The company remains optimistic about increasing its market share amid favourable economic fundamentals and anticipated policy measures in the upcoming Union Budget to boost infrastructure, private investments, and foreign direct investments (FDI).

Commenting on the performance, the Managing Director of Puravankara Ltd, Ashish Puravankara, said, “The growth in collections is a clear reflection of our strong operational efficiency. In 9MFY25, we achieved collections of Rs. 2,991 crore, a 19% Y-o-Y increase, with Rs. 993 crore in Q3FY25, a 6% increase Y-o-Y. Pre-sales for Q3FY25 reached Rs. 1,265 crore, up by 2% Y-o-Y. Keeping in line with our acquisition strategy and our growth plans for the current and next financial year, we have invested approximately Rs. 1,100 crores this fiscal, adding a potential GDV of around Rs. 10,500 crores. This includes our most recent acquisition in Kanakapura Road, Bengaluru.”

On January 14, 2025, Puravankara share price opened at ₹335.00, touching the day’s low at ₹325.75, as of 9:47 AM on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

HCLTech Reports 5.1% YoY Revenue Growth in Q3 FY25 Results; Declares ₹18 Interim Dividend

HCL Technologies Limited (HCLTech) reported its financial performance for the quarter ended December 31, 2024.

On January 13, 2025, HCLTech share price closed at ₹1,975.00, down by 1.01%. Notably, the stock price touched its 52-week high on January 13, 2025, at ₹2,012.20 on the NSE.

Q3 FY 2025 Financial Highlights

The company’s revenue stood at ₹29,890 crore, marking a 3.6% quarter-on-quarter (QoQ) growth and a 5.1% year-on-year (YoY) rise. The Earnings Before Interest and Tax (EBIT) reached ₹5,821 crore, representing 19.5% of revenue, with an 8.6% QoQ and 3.7% YoY increase. Net Income (NI) also demonstrated growth, reaching ₹4,591 crore, accounting for 15.4% of revenue, up 8.4% QoQ and 5.5% YoY.

Interim Dividend Declaration

To commemorate 25 years of its public listing, HCLTech’s Board of Directors declared a fourth interim dividend of ₹18 per equity share (₹2 face value). This includes a special dividend of ₹6 per share. The record date for this dividend is January 17, 2025, and the payment will be made on January 24, 2025.

FY25 Guidance

For FY25, HCLTech expects revenue growth of 4.5%–5.0% YoY in constant currency (CC). The company also projects services revenue growth to align with the same range. The EBIT margin guidance has been set at 18.0%–19.0%.

Expansion of Strategic Partnership with Microsoft

In another filing, HCLTech announced the expansion of its collaboration with Microsoft to revolutionise customer service experiences using generative AI and cloud-based solutions. The partnership focuses on Microsoft Dynamics 365 Contact Center, a Copilot-first solution that leverages advanced AI capabilities to enhance customer interactions, accelerate issue resolution, and boost efficiency. This move positions HCLTech as a frontrunner in offering cutting-edge solutions for customer service transformation.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Razorpay to Reverse-Flip Parent Entity to India; Plans IPO

India-born fintech startup Razorpay, which is currently incorporated in the US, has announced plans to reverse-flip its parent entity back to India in the next six months. Co-founder and CEO Harshil Mathur shared that the company is awaiting the necessary approvals for the process, which could take anywhere between 3 to 6 months.

Following the reverse flip, Razorpay expects to require 6-8 quarters of clean financials before considering an initial public offering (IPO). This means the company is likely to go public in at least two years.

Harshil Mathur stated that the reverse-flip process is expected to incur a tax outgo with payments to US authorities based on the company’s market valuation at the time of approval. Razorpay was last valued at $7.5 billion following its Series F funding round in 2021 and is optimistic about this move.

Razorpay’s Financial Performance and Global Expansion

Razorpay’s financials show strong growth, with its total income for FY 2023-24 reaching ₹2,501 crore, up from ₹2,293 crore the previous year. The company’s net profit surged to ₹34 crore, up from ₹7 crore. Online payments, its primary business, now contribute 75% of total revenue and are expected to grow at a 50% CAGR over the next few years.

The company’s offline payments and RazorpayX neo-banking business each contribute around 10-12% of total revenue. Razorpay also has international operations in the UAE and Malaysia and plans to expand into Singapore and other Southeast Asian markets in the near future. Despite its expansion, Razorpay aims for profitability in its new business verticals within 1-1.5 years, with a strong balance sheet that negates the need for immediate fund-raising.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Mangalore Refinery and Petrochemicals Launches 40 TMT Toluene Facility

Mangalore Refinery and Petrochemicals Limited (MRPL) has announced the launch of its Toluene production facility during a visit by the Hon’ble Minister of Petroleum and Natural Gas, Shri Hardeep Singh Puri, to its refinery. This milestone aligns with India’s vision of self-reliance and global competitiveness in the petrochemical sector.

Significant Contribution to Domestic Toluene Production

With an annual production capacity of 40 TMT, MRPL’s Toluene facility marks a substantial step toward reducing India’s dependency on imports. Currently, the domestic production of Toluene stands at 160 TMT against a demand of approximately 650 TMT per year. MRPL’s addition will help address this gap while saving $3 million annually in foreign exchange.

Toluene, a versatile aromatic hydrocarbon, is essential for industries such as pharmaceuticals, chemicals, paints, and defence. By enhancing domestic production, MRPL strengthens India’s industrial supply chain, enabling growth in key sectors.

The initiative is a testament to India’s progress toward becoming self-reliant in critical resources. MRPL’s efforts will not only boost the economy but also reduce dependency on imports, supporting industrial and economic growth in line with the Atmanirbhar Bharat mission.

On January 13, 2025, MRPL share price opened at ₹139.00, touching the day’s high at ₹144.44, as of 9:47 AM on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Wockhardt’s Zaynich® Shows 97% Efficacy Against Carbapenem-Resistant Infections

Wockhardt Limited informed the exchanges that in a groundbreaking clinical study, Zaynich® demonstrated exceptional efficacy, with over 97% clinical success in treating patients with infections caused by carbapenem-resistant Gram-negative pathogens, including meropenem-resistant strains.

Zaynich® is Wockhardt’s novel proprietary antibiotic that combines Zidebactam and Cefepime (WCK 5222).

The study addressed severe infections such as hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), bloodstream infections (BSI), complicated intra-abdominal infections (cIAI), and complicated urinary tract infections (cUTI). For bloodstream infections, HABP/VABP, and cIAI, Zaynich® achieved a remarkable 100% clinical efficacy.

High Efficacy and Pathogen Eradication Rates

Zaynich® also achieved notable pathogen eradication rates, including 91% for HABP/VABP and 100% for bloodstream infections. The study included critically ill patients across 15 tertiary care hospitals in India, focusing exclusively on carbapenem-resistant Gram-negative infections caused by pathogens like Acinetobacter spp., Pseudomonas spp., Klebsiella spp., and E. coli.

Using advanced molecular diagnostic technologies, the study highlighted Zaynich®’s effectiveness even against extensively drug-resistant (XDR) infections. Treatment durations ranged from 7 to 21 days, with the protocol receiving approval from the Drugs Controller General of India (DCGI).

Addressing the Global Threat of Antimicrobial Resistance

Zaynich® emerges as a game-changer in the fight against antimicrobial resistance (AMR), a growing global threat. Unlike current options such as colistin and polymyxins, which have significant toxicity and limited efficacy, Zaynich® provides a safer and more effective alternative.

It targets critical Gram-negative pathogens identified by the CDC and WHO, making it a valuable tool in combating life-threatening infections. With over 100 critically ill patients saved through its compassionate use in India and the US, Zaynich® sets a new benchmark for treating drug-resistant infections, offering hope for improved patient outcomes worldwide.

On January 13, 2025, Wockhardt share price (NSE: WOCKPHARMA) opened at ₹1,380.00, touching the day’s high at ₹1,442.00, as of 9:58 AM on the NSE.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Mid-Day Top Gainers and Losers on January 13, 2025: TCS & Infosys Shine

On January 13, 2025, as of 12 PM, the BSE Sensex was down 619.83 points (-0.80%) at 76,759.08, while the Nifty50 was down by 205.05 points (-0.88%) at 23,225.90. Among sectors, only the Nifty Realty dropped 4.29%.

As of January 13, 2025, 12:03 IST, the mid-day top gainers and losers are:

Mid-Day Top Gainers 

Symbol Open (₹) High (₹) Low (₹)
AXISBANK 1,026.60 1,063.00 1,023.25
INDUSINDBK 936.90 973.50 934.50
TCS 4,245.00 4,316.80 4,227.40
SHRIRAMFIN 530.05 540.70 524.05
INFY 1,956.00 1,982.80 1,949.00

  • Axis Bank

Axis Bank share price rose 1.43%, opening at ₹1,026.60 and touching the day’s high at ₹1,063.00.

  • IndusInd Bank

IndusInd Bank share price gained 1.34%, opening at ₹936.90 and touching the day’s high at ₹973.50.

  • TCS

Tata Consultancy Services share price surged 0.95%, opening at ₹4,245.00, hitting a high of ₹4,316.80.

  • Shriram Finance

Shriram Finance share price surged 0.49%, opening at ₹530.05, hitting a day’s high of ₹540.70.

  • Infosys 

Infosys Share Price rose by 0.11%, opening at ₹1,956.00, hitting a day’s high of ₹1,982.80.

Mid-Day Top Losers

Symbol Open (₹) High (₹) Low (₹)
TRENT 6,462.65 6,523.85 6,228.55
ADANIENT 2,365.00 2,365.00 2,295.00
APOLLOHOSP 7,000.00 7,000.00 6,812.05
GRASIM 2,329.95 2,348.20 2,302.00
EICHERMOT 5,010.00 5,024.20 4,930.00

  • Trent

Trent share price dropped 5.11%, opening at ₹6,462.65. The stock touched its day’s low at ₹6,228.55.

  • Adani Enterprises 

Adani Enterprises Share Price fell 3.11%, opening at ₹2,365.00. The stock touched its day’s low at ₹2,295.00.

  • Apollo Hospitals Enterprise

Apollo Hospitals share price dropped 2.99%, opening at ₹7,000.00. The stock touched its day’s low at ₹6,812.05.

  • Grasim Industries

Grasim Industries share price slipped 2.33%, opening at ₹2,329.95. The stock touched its day’s low at ₹2,302.00.

  • Eicher Motors

Eicher Motors share price slipped 2.39%, opening at ₹5,010.00. The stock touched its day’s low at ₹4,930.00.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

CESC Share Price Drops 3.29%; Posts 10.8% Revenue Growth in Q3 FY25 Results & Declares ₹4.50 Interim Dividend

CESC Ltd has been in focus on Monday. On January 13, 2025, CESC share price opened at ₹161.00, down from its previous close of ₹162.42. At 11:27 AM, the share price of CESC was trading at ₹157.07, down by 3.29% on the NSE. As of the same time, the stock touched its day’s low at ₹152.77.

Q3 FY 2025 Financial Highlights 

On January 10, 2025, the company provided an update for the third quarter of FY 2025. For Q3 FY25, the company reported gross revenue of ₹3,657 crore, reflecting a growth of 10.8% compared to ₹3,301 crore in Q3 FY24. The EBITDA for the quarter stood at ₹1,006 crore, an increase of 4.5% over ₹963 crore in the same quarter last year. However, the PAT (Profit After Tax) decreased by 6.3%, coming in at ₹282 crore, down from ₹301 crore in Q3 FY24.

For the nine-month period of FY25, the company reported a gross revenue of ₹13,345 crore, marking a 10.4% increase from ₹12,084 crore in the same period last year. The EBITDA for 9MFY25 stood at ₹3,206 crore, up by 4.1% from ₹3,079 crores in 9MFY24. PAT for the nine months was ₹1,043 crore, an increase of 1.1% compared to ₹1,032 crore in the previous year.

Interim Dividend Declaration and Record Date

The company has declared an interim dividend of ₹4.50 per equity share (i.e., 450%) on its paid-up equity share capital. This dividend will be payable to members whose names are listed in the Register of Members or those who appear as beneficial owners, as per the details provided by the Depositories, namely National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL), as of the close of business on January 16, 2025, the Record Date to determine eligibility for the interim dividend.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.